Alzheimer’s Treatment Market Report and Forecast 2025-2034
Description
The Alzheimer’s treatment market was valued at USD 45.99 Billion in 2024, driven by the increased elderly population and immune disorders. The market is anticipated to grow at a CAGR of 7.20% during the forecast period of 2025-2034 to achieve a value of USD 92.17 Billion by 2034. Major pharmaceutical companies and biotech startups are entering the space, with several pipeline drugs targeting disease progression rather than just symptoms. Public healthcare systems and private insurers are also preparing for higher costs as new, high-priced therapies come to market.
Alzheimer’s Treatment Market Overview
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting over 6.9 million Americans aged 65 and older, with global cases around 44 million. The treatment market is anticipated to grow at a CAGR of 7.20% during the forecast period of 2025-2034. It leads to memory loss, cognitive decline, and behavioural changes, causing significant mortality and economic burden, costs in the U.S. reached USD 360 billion in 2024. Current treatments focus on symptom relief using cholinesterase inhibitors and memantine, while research continues on disease-modifying therapies targeting amyloid plaques and tau proteins to slow progression.
Alzheimer’s Treatment Market Growth Drivers
New Approvals Driving Alzheimer’s Treatment Market Expansion Worldwide
For instance, increasing demand for early-intervention therapies and rising investment in neurodegenerative drug R&D are fuelling market growth. For instance, in May 2025, Eisai and Biogen announced that the U.S. FDA accepted a Supplemental Biologics License Application (sBLA) for Leqembi as a maintenance treatment for early Alzheimer’s. The application seeks to enable less frequent dosing after initial therapy. This development could significantly improve patient compliance and accessibility, boosting long-term market adoption of disease-modifying Alzheimer’s treatments.
Surge in Government Approvals to Boost Alzheimer’s Treatment Market Demand
The rising prevalence of early-stage Alzheimer’s and the push for region-specific drug approvals are key market drivers. For instance, in May 2025, Australia approved donanemab (marketed as Kisunla), an anti-amyloid drug for early Alzheimer’s, following its U.S. success. The approval supports expanding access to cutting-edge treatments across new geographies. This move is poised to strengthen market value in the Asia-Pacific region, encouraging faster adoption and increased regional regulatory momentum in Alzheimer’s care.
Alzheimer’s Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rise in Research Initiatives and Real-World Data Supporting Alzheimer’s Drug Tolerability to Boost Market Growth
The growing demand for real-world validation and better patient adherence insights is shaping treatment decisions. For instance, in May 2025, a Washington University study found that an Alzheimer’s drug designed to slow cognitive decline was well-tolerated by patients outside of clinical trial settings. This trend of leveraging real-world data improves prescriber confidence and supports broader adoption of therapies. It is likely to enhance market growth by demonstrating practical efficacy and safety across more diverse Alzheimer’s patient populations.
Biomarker Integration to Enhance Precision in Alzheimer’s Treatment Market
Increasing focus on early intervention and precision medicine is transforming the Alzheimer’s treatment paradigm. For instance, in April 2025, Roche announced that it is advancing biomarker-based diagnostic and treatment approaches, aligning with next-generation targeted drug development. These innovations allow for earlier detection and individualized therapy, which could significantly improve outcomes. As biomarker integration becomes more prominent, the Alzheimer’s treatment market is expected to witness accelerated development, with new opportunities in both diagnostics and therapeutics.
Increasing Focus on Combination Therapies in Alzheimer’s Treatment to Influence Market Size Positively
The growing research is emphasizing on combining multiple therapeutic approaches, such as anti-amyloid agents with tau protein inhibitors or neuroinflammation modulators, to address Alzheimer’s complex pathology. This trend reflects the understanding that targeting a single pathway may be insufficient, encouraging the development of pipelines to diversify. Combination therapies could improve clinical outcomes, driving market expansion by offering more comprehensive treatment options for patients at various disease stages.
Expansion of Patient Support Programs to Enhance Market Penetration
Pharmaceutical companies are increasingly investing in patient support and education programs to improve medication adherence and long-term treatment success. These initiatives include counseling, digital reminders, and caregiver training, which help overcome barriers to sustained therapy use. Enhanced adherence improves clinical outcomes and patient quality of life, thereby increasing demand and market growth for Alzheimer’s drugs as more patients maintain consistent treatment regimens.
Alzheimer’s Treatment Market Segmentation
Alzheimer’s Treatment Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Cholinesterase Inhibitors to Lead the Segmentation by Drug Class
Cholinesterase inhibitors are set to lead the market due to their proven efficacy in managing mild to moderate symptoms. Drugs like donepezil, rivastigmine, and galantamine help enhance neurotransmitter activity, improving memory and cognitive function. Their widespread prescription, long-established clinical use, and minimal safety concerns contribute to continued demand. As the aging population grows, these therapies will remain essential, supported by ongoing clinical enhancements and rising public and professional awareness about early-stage Alzheimer’s management.
Hospital Pharmacy Dominating the Segment by Distribution Channel
Hospital pharmacies are expected to lead the market by end user due to their role in initiating treatment following formal diagnosis. Complex Alzheimer’s medications often require physician supervision, which hospital settings efficiently provide. Hospitals also serve as primary sites for clinical trials and new therapy rollouts. With the growing number of specialized neurology departments and inpatient care units for cognitive disorders, hospital pharmacies will remain central to drug dispensing, driving sustained market development.
Alzheimer’s Treatment Market Analysis by Region
The United States has the largest Alzheimer’s treatment market. Several factors drive this, such as, an aging population, early diagnosis rates, significant healthcare spending, and rapid adoption of new drugs. Medicare covers many treatments, and recent FDA approvals (like Leqembi and donanemab) have stirred both interest and debate. The market is competitive, with major pharmaceutical companies investing heavily in R&D. Public pressure and advocacy groups keep Alzheimer’s high on the policy agenda. In the United Kingdom, the NHS plays a central role in market dynamics. Access to newer treatments is slower due to NICE cost-effectiveness evaluations. The focus is on early intervention and non-drug therapies, though biologics are gaining attention. Government funding for dementia research has increased, but uptake of novel drugs remains cautious.
Leading Players in the Alzheimer’s Treatment Market
The key features of the market report comprise clinical trials analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
F.Hoffmann La Roche
Headquartered in Basel, Switzerland, F. Hoffmann-La Roche was established in 1896 and is a global leader in pharmaceuticals and diagnostics. In the Alzheimer’s treatment market, Roche is recognized for its innovative biologics and targeted therapies. Its key candidates include gantenerumab and crenezumab, developed to address amyloid plaque build-up. Roche invests heavily in neurology-focused research, aiming to advance disease-modifying treatments that slow Alzheimer’s progression and improve cognitive outcomes, reinforcing its commitment to neurodegenerative disease care.
H. Lundbeck
Founded in 1915 and headquartered in Copenhagen, Denmark, H. Lundbeck A/S is a global pharmaceutical company focused on brain diseases. In Alzheimer’s treatment, Lundbeck markets memantine-based products like Ebixa and Namenda, which are commonly prescribed for moderate to severe cases. The company continues to invest in neuroscience R&D to discover new mechanisms of action for treating neurodegeneration, emphasizing its dedication to improving patient outcomes in Alzheimer’s and other central nervous system disorders.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd., headquartered in Ahmedabad, India, was established in 1952. The company has been advancing its footprint in the Alzheimer’s treatment market through affordable generics and biosimilar offerings. Zydus has also engaged in developing novel therapies, including investigational drugs targeting neuroinflammation and amyloid-related pathways. Its commitment to accessible healthcare and innovation supports the global fight against Alzheimer’s, especially in cost-sensitive regions where advanced therapeutics remain a challenge.
Pfizer Inc
Founded in 1849, Pfizer Inc. is headquartered in New York City, USA, and is a globally renowned pharmaceutical leader. In the Alzheimer’s treatment space, Pfizer co-developed Aricept (donepezil), one of the most widely prescribed drugs for managing symptoms. Although it has reduced direct involvement in recent years, Pfizer continues to support research collaborations and funding for innovative neurodegenerative therapies, reflecting its legacy role and sustained influence in advancing Alzheimer’s care and neurological research.
Other key players in the market include Baxter International Inc., Abbvie, Inc., Eisai Co. Ltd., Merz Pharma, AstraZeneca, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., ONO Pharmaceutical Industries Ltd., VTV Therapeutics, and Biogen.
Key Questions Answered in the Alzheimer’s Treatment Market
Alzheimer’s Treatment Market Overview
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting over 6.9 million Americans aged 65 and older, with global cases around 44 million. The treatment market is anticipated to grow at a CAGR of 7.20% during the forecast period of 2025-2034. It leads to memory loss, cognitive decline, and behavioural changes, causing significant mortality and economic burden, costs in the U.S. reached USD 360 billion in 2024. Current treatments focus on symptom relief using cholinesterase inhibitors and memantine, while research continues on disease-modifying therapies targeting amyloid plaques and tau proteins to slow progression.
Alzheimer’s Treatment Market Growth Drivers
New Approvals Driving Alzheimer’s Treatment Market Expansion Worldwide
For instance, increasing demand for early-intervention therapies and rising investment in neurodegenerative drug R&D are fuelling market growth. For instance, in May 2025, Eisai and Biogen announced that the U.S. FDA accepted a Supplemental Biologics License Application (sBLA) for Leqembi as a maintenance treatment for early Alzheimer’s. The application seeks to enable less frequent dosing after initial therapy. This development could significantly improve patient compliance and accessibility, boosting long-term market adoption of disease-modifying Alzheimer’s treatments.
Surge in Government Approvals to Boost Alzheimer’s Treatment Market Demand
The rising prevalence of early-stage Alzheimer’s and the push for region-specific drug approvals are key market drivers. For instance, in May 2025, Australia approved donanemab (marketed as Kisunla), an anti-amyloid drug for early Alzheimer’s, following its U.S. success. The approval supports expanding access to cutting-edge treatments across new geographies. This move is poised to strengthen market value in the Asia-Pacific region, encouraging faster adoption and increased regional regulatory momentum in Alzheimer’s care.
Alzheimer’s Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rise in Research Initiatives and Real-World Data Supporting Alzheimer’s Drug Tolerability to Boost Market Growth
The growing demand for real-world validation and better patient adherence insights is shaping treatment decisions. For instance, in May 2025, a Washington University study found that an Alzheimer’s drug designed to slow cognitive decline was well-tolerated by patients outside of clinical trial settings. This trend of leveraging real-world data improves prescriber confidence and supports broader adoption of therapies. It is likely to enhance market growth by demonstrating practical efficacy and safety across more diverse Alzheimer’s patient populations.
Biomarker Integration to Enhance Precision in Alzheimer’s Treatment Market
Increasing focus on early intervention and precision medicine is transforming the Alzheimer’s treatment paradigm. For instance, in April 2025, Roche announced that it is advancing biomarker-based diagnostic and treatment approaches, aligning with next-generation targeted drug development. These innovations allow for earlier detection and individualized therapy, which could significantly improve outcomes. As biomarker integration becomes more prominent, the Alzheimer’s treatment market is expected to witness accelerated development, with new opportunities in both diagnostics and therapeutics.
Increasing Focus on Combination Therapies in Alzheimer’s Treatment to Influence Market Size Positively
The growing research is emphasizing on combining multiple therapeutic approaches, such as anti-amyloid agents with tau protein inhibitors or neuroinflammation modulators, to address Alzheimer’s complex pathology. This trend reflects the understanding that targeting a single pathway may be insufficient, encouraging the development of pipelines to diversify. Combination therapies could improve clinical outcomes, driving market expansion by offering more comprehensive treatment options for patients at various disease stages.
Expansion of Patient Support Programs to Enhance Market Penetration
Pharmaceutical companies are increasingly investing in patient support and education programs to improve medication adherence and long-term treatment success. These initiatives include counseling, digital reminders, and caregiver training, which help overcome barriers to sustained therapy use. Enhanced adherence improves clinical outcomes and patient quality of life, thereby increasing demand and market growth for Alzheimer’s drugs as more patients maintain consistent treatment regimens.
Alzheimer’s Treatment Market Segmentation
Alzheimer’s Treatment Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Early-onset Alzheimer’s
- Late onset Alzheimer’s
- Familial Form Alzheimer’s
- Cholinesterase Inhibitors
- Donepezil
- Rivastigmine
- Galantamine
- N-Methyl-D-Aspartate (NMDA) Receptor Antagonist
- Memantine
- Others
- Oral
- Parenteral
- Others
- Hospital
- Specialty Clinics
- Homecare Settings
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Cholinesterase Inhibitors to Lead the Segmentation by Drug Class
Cholinesterase inhibitors are set to lead the market due to their proven efficacy in managing mild to moderate symptoms. Drugs like donepezil, rivastigmine, and galantamine help enhance neurotransmitter activity, improving memory and cognitive function. Their widespread prescription, long-established clinical use, and minimal safety concerns contribute to continued demand. As the aging population grows, these therapies will remain essential, supported by ongoing clinical enhancements and rising public and professional awareness about early-stage Alzheimer’s management.
Hospital Pharmacy Dominating the Segment by Distribution Channel
Hospital pharmacies are expected to lead the market by end user due to their role in initiating treatment following formal diagnosis. Complex Alzheimer’s medications often require physician supervision, which hospital settings efficiently provide. Hospitals also serve as primary sites for clinical trials and new therapy rollouts. With the growing number of specialized neurology departments and inpatient care units for cognitive disorders, hospital pharmacies will remain central to drug dispensing, driving sustained market development.
Alzheimer’s Treatment Market Analysis by Region
The United States has the largest Alzheimer’s treatment market. Several factors drive this, such as, an aging population, early diagnosis rates, significant healthcare spending, and rapid adoption of new drugs. Medicare covers many treatments, and recent FDA approvals (like Leqembi and donanemab) have stirred both interest and debate. The market is competitive, with major pharmaceutical companies investing heavily in R&D. Public pressure and advocacy groups keep Alzheimer’s high on the policy agenda. In the United Kingdom, the NHS plays a central role in market dynamics. Access to newer treatments is slower due to NICE cost-effectiveness evaluations. The focus is on early intervention and non-drug therapies, though biologics are gaining attention. Government funding for dementia research has increased, but uptake of novel drugs remains cautious.
Leading Players in the Alzheimer’s Treatment Market
The key features of the market report comprise clinical trials analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
F.Hoffmann La Roche
Headquartered in Basel, Switzerland, F. Hoffmann-La Roche was established in 1896 and is a global leader in pharmaceuticals and diagnostics. In the Alzheimer’s treatment market, Roche is recognized for its innovative biologics and targeted therapies. Its key candidates include gantenerumab and crenezumab, developed to address amyloid plaque build-up. Roche invests heavily in neurology-focused research, aiming to advance disease-modifying treatments that slow Alzheimer’s progression and improve cognitive outcomes, reinforcing its commitment to neurodegenerative disease care.
H. Lundbeck
Founded in 1915 and headquartered in Copenhagen, Denmark, H. Lundbeck A/S is a global pharmaceutical company focused on brain diseases. In Alzheimer’s treatment, Lundbeck markets memantine-based products like Ebixa and Namenda, which are commonly prescribed for moderate to severe cases. The company continues to invest in neuroscience R&D to discover new mechanisms of action for treating neurodegeneration, emphasizing its dedication to improving patient outcomes in Alzheimer’s and other central nervous system disorders.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd., headquartered in Ahmedabad, India, was established in 1952. The company has been advancing its footprint in the Alzheimer’s treatment market through affordable generics and biosimilar offerings. Zydus has also engaged in developing novel therapies, including investigational drugs targeting neuroinflammation and amyloid-related pathways. Its commitment to accessible healthcare and innovation supports the global fight against Alzheimer’s, especially in cost-sensitive regions where advanced therapeutics remain a challenge.
Pfizer Inc
Founded in 1849, Pfizer Inc. is headquartered in New York City, USA, and is a globally renowned pharmaceutical leader. In the Alzheimer’s treatment space, Pfizer co-developed Aricept (donepezil), one of the most widely prescribed drugs for managing symptoms. Although it has reduced direct involvement in recent years, Pfizer continues to support research collaborations and funding for innovative neurodegenerative therapies, reflecting its legacy role and sustained influence in advancing Alzheimer’s care and neurological research.
Other key players in the market include Baxter International Inc., Abbvie, Inc., Eisai Co. Ltd., Merz Pharma, AstraZeneca, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., ONO Pharmaceutical Industries Ltd., VTV Therapeutics, and Biogen.
Key Questions Answered in the Alzheimer’s Treatment Market
- What was the Alzheimer’s treatment market value in 2024?
- What is the Alzheimer’s treatment market forecast outlook for 2025-2034?
- What are the major factors aiding the Alzheimer’s treatment market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major Alzheimer’s treatment market trends?
- Which drug class will lead the market segment?
- Which end user will lead the market segment?
- Who are the key players involved in the Alzheimer’s treatment market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Alzheimer’s Treatment Market Overview: 8 Major Markets
- 3.1 Alzheimer’s Treatment Market Historical Value (2018-2024)
- 3.2 Alzheimer’s Treatment Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Alzheimer’s Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Alzheimer Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence of Alzheimer, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 Germany
- 7.1.1.4 France
- 7.1.1.5 Italy
- 7.1.1.6 Spain
- 7.1.1.7 India
- 7.1.1.8 Japan
- 7.2 Total Diagnosed Cases of Alzheimer, By Country
- 7.3 Gender-specific Prevalence of Alzheimer’s, By Country
- 7.4 Age-specific Prevalence of Alzheimer’s, By Country
- 7.5 Treatment Seeking Rate of Alzheimer’s, By Country
- 8 Alzheimer’s Treatment Market Landscape: 8 Major Markets
- 8.1 Alzheimer’s Treatment Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Alzheimer’s Treatment Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Drug Class
- 8.2.3 Analysis by Route of Administration
- 9 Clinical Trials and Pipeline Analysis
- 9.1 Analysis by Trial Registration Year
- 9.2 Analysis by Trial Status
- 9.3 Analysis by Trial Phase
- 9.4 Analysis by Therapeutic Area
- 9.5 Analysis by Geography
- 9.6 Drug Pipeline Assessment
- 10 Alzheimer’s Treatment Market Challenges and Unmet Needs
- 10.1 Therapy Pathway Challenges
- 10.2 Compliance and Drop-Out Analysis
- 10.3 Awareness and Prevention Gaps
- 11 Cost of Treatment
- 12 Alzheimer’s Treatment Market Dynamics
- 12.1 Market Drivers and Constraints
- 12.2 SWOT Analysis
- 12.2.1 Strengths
- 12.2.2 Weaknesses
- 12.2.3 Opportunities
- 12.2.4 Threats
- 12.3 PESTEL Analysis
- 12.3.1 Political
- 12.3.2 Economic
- 12.3.3 Social
- 12.3.4 Technological
- 12.3.5 Legal
- 12.3.6 Environment
- 12.4 Porter’s Five Forces Model
- 12.4.1 Bargaining Power of Suppliers
- 12.4.2 Bargaining Power of Buyers
- 12.4.3 Threat of New Entrants
- 12.4.4 Threat of Substitutes
- 12.4.5 Degree of Rivalry
- 12.5 Key Demand Indicators
- 12.6 Key Price Indicators
- 12.7 Industry Events, Initiatives, and Trends
- 12.8 Value Chain Analysis
- 13 Alzheimer’s Treatment Market Segmentation: 8 Major Markets
- 13.1 Alzheimer’s Treatment Market (2018-2034) by Type
- 13.1.1 Market Overview
- 13.1.2 Early-onset Alzheimer’s
- 13.1.3 Late onset Alzheimer’s
- 13.1.4 Familial Form Alzheimer’s
- 13.2 Alzheimer’s Treatment Market (2018-2034) by Drug Class
- 13.2.1 Market Overview
- 13.2.2 Cholinesterase Inhibitors
- 13.2.2.1 Donepezil
- 13.2.2.2 Rivastigmine
- 13.2.2.3 Galantamine
- 13.2.3 NMDA Receptor Antagonists
- 13.2.3.1 Memantine
- 13.2.4 Others
- 13.3 Alzheimer’s Treatment Market (2018-2034) by Route of Administration
- 13.3.1 Market Overview
- 13.3.2 Oral
- 13.3.3 Parenteral
- 13.3.4 Others
- 13.4 Alzheimer’s Treatment Market (2018-2034) by End User
- 13.4.1 Market Overview
- 13.4.2 Hospital
- 13.4.3 Specialty Clinics
- 13.4.4 Homecare Settings
- 13.4.5 Others
- 13.5 Alzheimer’s Treatment Market (2018-2034) by Distribution Channel
- 13.5.1 Market Overview
- 13.5.2 Hospital Pharmacy
- 13.5.3 Retail Pharmacy
- 13.5.4 Online Pharmacy
- 13.6 Alzheimer’s Treatment Market (2018-2034) by Region
- 13.6.1 Market Overview
- 13.6.2 United States
- 13.6.3 United Kingdom
- 13.6.4 Germany
- 13.6.5 France
- 13.6.6 Italy
- 13.6.7 Spain
- 13.6.8 Japan
- 13.6.9 India
- 14 United States Alzheimer’s Treatment Market (218-2034)
- 14.1 United States Alzheimer’s Treatment Market (2018-2034) by Type
- 14.1.1 Market Overview
- 14.1.2 Early-onset Alzheimer’s
- 14.1.3 Late onset Alzheimer’s
- 14.1.4 Familial Form Alzheimer’s
- 14.2 United States Alzheimer’s Treatment Market (2018-2034) by Drug Class
- 14.2.1 Market Overview
- 14.2.2 Cholinesterase Inhibitors
- 14.2.2.1 Donepezil
- 14.2.2.2 Rivastigmine
- 14.2.2.3 Galantamine
- 14.2.3 NMDA Receptor Antagonists
- 14.2.3.1 Memantine
- 14.2.4 Others
- 14.3 United States Alzheimer’s Treatment Market (2018-2034) by Route of Administration
- 14.3.1 Market Overview
- 14.3.2 Oral
- 14.3.3 Parenteral
- 14.3.4 Others
- 14.4 United States Alzheimer’s Treatment Market (2018-2034) by End User
- 14.4.1 Market Overview
- 14.4.2 Hospital
- 14.4.3 Specialty Clinics
- 14.4.4 Homecare Settings
- 14.4.5 Others
- 14.5 United States Alzheimer’s Treatment Market (2018-2034) by Distribution Channel
- 14.5.1 Market Overview
- 14.5.2 Hospital Pharmacy
- 14.5.3 Retail Pharmacy
- 14.5.4 Online Pharmacy
- 15 United Kingdom Alzheimer’s Treatment Market (218-2034)
- 15.1 United Kingdom Alzheimer’s Treatment Market (2018-2034) by Type
- 15.1.1 Market Overview
- 15.1.2 Early-onset Alzheimer’s
- 15.1.3 Late onset Alzheimer’s
- 15.1.4 Familial Form Alzheimer’s
- 15.2 United Kingdom Alzheimer’s Treatment Market (2018-2034) by Drug Class
- 15.2.1 Market Overview
- 15.2.2 Cholinesterase Inhibitors
- 15.2.2.1 Donepezil
- 15.2.2.2 Rivastigmine
- 15.2.2.3 Galantamine
- 15.2.3 NMDA Receptor Antagonists
- 15.2.3.1 Memantine
- 15.2.4 Others
- 15.3 United Kingdom Alzheimer’s Treatment Market (2018-2034) by Route of Administration
- 15.3.1 Market Overview
- 15.3.2 Oral
- 15.3.3 Parenteral
- 15.3.4 Others
- 15.4 United Kingdom Alzheimer’s Treatment Market (2018-2034) by End User
- 15.4.1 Market Overview
- 15.4.2 Hospital
- 15.4.3 Specialty Clinics
- 15.4.4 Homecare Settings
- 15.4.5 Others
- 15.5 United Kingdom Alzheimer’s Treatment Market (2018-2034) by Distribution Channel
- 15.5.1 Market Overview
- 15.5.2 Hospital Pharmacy
- 15.5.3 Retail Pharmacy
- 15.5.4 Online Pharmacy
- 16 Germany Alzheimer’s Treatment Market (218-2034)
- 16.1 Germany Alzheimer’s Treatment Market (2018-2034) by Type
- 16.1.1 Market Overview
- 16.1.2 Early-onset Alzheimer’s
- 16.1.3 Late onset Alzheimer’s
- 16.1.4 Familial Form Alzheimer’s
- 16.2 Germany Alzheimer’s Treatment Market (2018-2034) by Drug Class
- 16.2.1 Market Overview
- 16.2.2 Cholinesterase Inhibitors
- 16.2.2.1 Donepezil
- 16.2.2.2 Rivastigmine
- 16.2.2.3 Galantamine
- 16.2.3 NMDA Receptor Antagonists
- 16.2.3.1 Memantine
- 16.2.4 Others
- 16.3 Germany Alzheimer’s Treatment Market (2018-2034) by Route of Administration
- 16.3.1 Market Overview
- 16.3.2 Oral
- 16.3.3 Parenteral
- 16.3.4 Others
- 16.4 Germany Alzheimer’s Treatment Market (2018-2034) by End User
- 16.4.1 Market Overview
- 16.4.2 Hospital
- 16.4.3 Specialty Clinics
- 16.4.4 Homecare Settings
- 16.4.5 Others
- 16.5 Germany Alzheimer’s Treatment Market (2018-2034) by Distribution Channel
- 16.5.1 Market Overview
- 16.5.2 Hospital Pharmacy
- 16.5.3 Retail Pharmacy
- 16.5.4 Online Pharmacy
- 17 France Alzheimer’s Treatment Market (218-2034)
- 17.1 France Alzheimer’s Treatment Market (2018-2034) by Type
- 17.1.1 Market Overview
- 17.1.2 Early-onset Alzheimer’s
- 17.1.3 Late onset Alzheimer’s
- 17.1.4 Familial Form Alzheimer’s
- 17.2 France Alzheimer’s Treatment Market (2018-2034) by Drug Class
- 17.2.1 Market Overview
- 17.2.2 Cholinesterase Inhibitors
- 17.2.2.1 Donepezil
- 17.2.2.2 Rivastigmine
- 17.2.2.3 Galantamine
- 17.2.3 NMDA Receptor Antagonists
- 17.2.3.1 Memantine
- 17.2.4 Others
- 17.3 France Alzheimer’s Treatment Market (2018-2034) by Route of Administration
- 17.3.1 Market Overview
- 17.3.2 Oral
- 17.3.3 Parenteral
- 17.3.4 Others
- 17.4 France Alzheimer’s Treatment Market (2018-2034) by End User
- 17.4.1 Market Overview
- 17.4.2 Hospital
- 17.4.3 Specialty Clinics
- 17.4.4 Homecare Settings
- 17.4.5 Others
- 17.5 France Alzheimer’s Treatment Market (2018-2034) by Distribution Channel
- 17.5.1 Market Overview
- 17.5.2 Hospital Pharmacy
- 17.5.3 Retail Pharmacy
- 17.5.4 Online Pharmacy
- 18 Italy Alzheimer’s Treatment Market (218-2034)
- 18.1 Italy Alzheimer’s Treatment Market (2018-2034) by Type
- 18.1.1 Market Overview
- 18.1.2 Early-onset Alzheimer’s
- 18.1.3 Late onset Alzheimer’s
- 18.1.4 Familial Form Alzheimer’s
- 18.2 Italy Alzheimer’s Treatment Market (2018-2034) by Drug Class
- 18.2.1 Market Overview
- 18.2.2 Cholinesterase Inhibitors
- 18.2.2.1 Donepezil
- 18.2.2.2 Rivastigmine
- 18.2.2.3 Galantamine
- 18.2.3 NMDA Receptor Antagonists
- 18.2.3.1 Memantine
- 18.2.4 Others
- 18.3 Italy Alzheimer’s Treatment Market (2018-2034) by Route of Administration
- 18.3.1 Market Overview
- 18.3.2 Oral
- 18.3.3 Parenteral
- 18.3.4 Others
- 18.4 Italy Alzheimer’s Treatment Market (2018-2034) by End User
- 18.4.1 Market Overview
- 18.4.2 Hospital
- 18.4.3 Specialty Clinics
- 18.4.4 Homecare Settings
- 18.4.5 Others
- 18.5 Italy Alzheimer’s Treatment Market (2018-2034) by Distribution Channel
- 18.5.1 Market Overview
- 18.5.2 Hospital Pharmacy
- 18.5.3 Retail Pharmacy
- 18.5.4 Online Pharmacy
- 19 Spain Alzheimer’s Treatment Market (218-2034)
- 19.1 Spain Alzheimer’s Treatment Market (2018-2034) by Type
- 19.1.1 Market Overview
- 19.1.2 Early-onset Alzheimer’s
- 19.1.3 Late onset Alzheimer’s
- 19.1.4 Familial Form Alzheimer’s
- 19.2 Spain Alzheimer’s Treatment Market (2018-2034) by Drug Class
- 19.2.1 Market Overview
- 19.2.2 Cholinesterase Inhibitors
- 19.2.2.1 Donepezil
- 19.2.2.2 Rivastigmine
- 19.2.2.3 Galantamine
- 19.2.3 NMDA Receptor Antagonists
- 19.2.3.1 Memantine
- 19.2.4 Others
- 19.3 Spain Alzheimer’s Treatment Market (2018-2034) by Route of Administration
- 19.3.1 Market Overview
- 19.3.2 Oral
- 19.3.3 Parenteral
- 19.3.4 Others
- 19.4 Spain Alzheimer’s Treatment Market (2018-2034) by End User
- 19.4.1 Market Overview
- 19.4.2 Hospital
- 19.4.3 Specialty Clinics
- 19.4.4 Homecare Settings
- 19.4.5 Others
- 19.5 Spain Alzheimer’s Treatment Market (2018-2034) by Distribution Channel
- 19.5.1 Market Overview
- 19.5.2 Hospital Pharmacy
- 19.5.3 Retail Pharmacy
- 19.5.4 Online Pharmacy
- 20 Japan Alzheimer’s Treatment Market (218-2034)
- 20.1 Japan Alzheimer’s Treatment Market (2018-2034) by Type
- 20.1.1 Market Overview
- 20.1.2 Early-onset Alzheimer’s
- 20.1.3 Late onset Alzheimer’s
- 20.1.4 Familial Form Alzheimer’s
- 20.2 Japan Alzheimer’s Treatment Market (2018-2034) by Drug Class
- 20.2.1 Market Overview
- 20.2.2 Cholinesterase Inhibitors
- 20.2.2.1 Donepezil
- 20.2.2.2 Rivastigmine
- 20.2.2.3 Galantamine
- 20.2.3 NMDA Receptor Antagonists
- 20.2.3.1 Memantine
- 20.2.4 Others
- 20.3 Japan Alzheimer’s Treatment Market (2018-2034) by Route of Administration
- 20.3.1 Market Overview
- 20.3.2 Oral
- 20.3.3 Parenteral
- 20.3.4 Others
- 20.4 Japan Alzheimer’s Treatment Market (2018-2034) by End User
- 20.4.1 Market Overview
- 20.4.2 Hospital
- 20.4.3 Specialty Clinics
- 20.4.4 Homecare Settings
- 20.4.5 Others
- 20.5 Japan Alzheimer’s Treatment Market (2018-2034) by Distribution Channel
- 20.5.1 Market Overview
- 20.5.2 Hospital Pharmacy
- 20.5.3 Retail Pharmacy
- 20.5.4 Online Pharmacy
- 21 India Alzheimer’s Treatment Market (218-2034)
- 21.1 India Alzheimer’s Treatment Market (2018-2034) by Type
- 21.1.1 Market Overview
- 21.1.2 Early-onset Alzheimer’s
- 21.1.3 Late onset Alzheimer’s
- 21.1.4 Familial Form Alzheimer’s
- 21.2 India Alzheimer’s Treatment Market (2018-2034) by Drug Class
- 21.2.1 Market Overview
- 21.2.2 Cholinesterase Inhibitors
- 21.2.2.1 Donepezil
- 21.2.2.2 Rivastigmine
- 21.2.2.3 Galantamine
- 21.2.3 NMDA Receptor Antagonists
- 21.2.3.1 Memantine
- 21.2.4 Others
- 21.3 India Alzheimer’s Treatment Market (2018-2034) by Route of Administration
- 21.3.1 Market Overview
- 21.3.2 Oral
- 21.3.3 Parenteral
- 21.3.4 Others
- 21.4 India Alzheimer’s Treatment Market (2018-2034) by End User
- 21.4.1 Market Overview
- 21.4.2 Hospital
- 21.4.3 Specialty Clinics
- 21.4.4 Homecare Settings
- 21.4.5 Others
- 21.5 India Alzheimer’s Treatment Market (2018-2034) by Distribution Channel
- 21.5.1 Market Overview
- 21.5.2 Hospital Pharmacy
- 21.5.3 Retail Pharmacy
- 21.5.4 Online Pharmacy
- 22 Regulatory Framework
- 22.1 Regulatory Overview
- 22.2 US FDA
- 22.3 EU EMA
- 22.4 INDIA CDSCO
- 22.5 JAPAN PMDA
- 22.6 Others
- 23 Patent Analysis
- 23.1 Analysis by Technology
- 23.2 Analysis by Publication Year
- 23.3 Analysis by Issuing Authority
- 23.4 Analysis by Patent Age
- 23.5 Analysis by CPC Codes
- 23.6 Analysis by Patent Valuation
- 24 Grant Analysis
- 24.1 Analysis by Year
- 24.2 Analysis by Amount Awarded
- 24.3 Analysis by Issuing Authority
- 24.4 Analysis by Grant Application
- 24.5 Analysis by Funding Institute
- 24.6 Analysis by NIH Departments
- 24.7 Analysis by Recipient Organization
- 25 Funding and Investment Analysis
- 25.1 Analysis by Funding Instances
- 25.2 Analysis by Type of Funding
- 25.3 Analysis by Funding Amount
- 25.4 Analysis by Leading Players
- 25.5 Analysis by Leading Investors
- 25.6 Analysis by Geography
- 26 Strategic Initiatives
- 26.1 Analysis by Partnership Instances
- 26.2 Analysis by Type of Initiatives
- 26.3 Analysis by Leading Players
- 26.4 Analysis by Geography
- 27 Supplier Landscape
- 27.1 Market Share Analysis, by Top 5 Companies
- 27.2 Abbvie Inc.
- 27.2.1 Financial Analysis
- 27.2.2 Product Portfolio
- 27.2.3 Demographic Reach and Achievements
- 27.2.4 Company News and Developments
- 27.2.5 Certifications
- 27.3 F Hoffmann La Roche
- 27.3.1 Financial Analysis
- 27.3.2 Product Portfolio
- 27.3.3 Demographic Reach and Achievements
- 27.3.4 Company News and Developments
- 27.3.5 Certifications
- 27.4 H. Lundbeck
- 27.4.1 Financial Analysis
- 27.4.2 Product Portfolio
- 27.4.3 Demographic Reach and Achievements
- 27.4.4 Company News and Developments
- 27.4.5 Certifications
- 27.5 Zydus Lifesciences Ltd.
- 27.5.1 Financial Analysis
- 27.5.2 Product Portfolio
- 27.5.3 Demographic Reach and Achievements
- 27.5.4 Company News and Developments
- 27.5.5 Certifications
- 27.6 Baxter International Inc.
- 27.6.1 Financial Analysis
- 27.6.2 Product Portfolio
- 27.6.3 Demographic Reach and Achievements
- 27.6.4 Company News and Developments
- 27.6.5 Certifications
- 27.7 Eisai Co. Ltd
- 27.7.1 Financial Analysis
- 27.7.2 Product Portfolio
- 27.7.3 Demographic Reach and Achievements
- 27.7.4 Company News and Developments
- 27.7.5 Certifications
- 27.8 Pfizer Inc.
- 27.8.1 Financial Analysis
- 27.8.2 Product Portfolio
- 27.8.3 Demographic Reach and Achievements
- 27.8.4 Company News and Developments
- 27.8.5 Certifications
- 27.9 Merz Pharma
- 27.9.1 Financial Analysis
- 27.9.2 Product Portfolio
- 27.9.3 Demographic Reach and Achievements
- 27.9.4 Company News and Developments
- 27.9.5 Certifications
- 27.10 AstraZeneca
- 27.10.1 Financial Analysis
- 27.10.2 Product Portfolio
- 27.10.3 Demographic Reach and Achievements
- 27.10.4 Company News and Developments
- 27.10.5 Certifications
- 27.11 Eli Lilly and Company
- 27.11.1 Financial Analysis
- 27.11.2 Product Portfolio
- 27.11.3 Demographic Reach and Achievements
- 27.11.4 Company News and Developments
- 27.11.5 Certifications
- 27.12 Teva Pharmaceutical Industries Ltd.
- 27.12.1 Financial Analysis
- 27.12.2 Product Portfolio
- 27.12.3 Demographic Reach and Achievements
- 27.12.4 Company News and Developments
- 27.12.5 Certifications
- 27.13 ONO Pharmaceutical Co. Ltd.
- 27.13.1 Financial Analysis
- 27.13.2 Product Portfolio
- 27.13.3 Demographic Reach and Achievements
- 27.13.4 Company News and Developments
- 27.13.5 Certifications
- 27.14 VTV Therapeutics
- 27.14.1 Financial Analysis
- 27.14.2 Product Portfolio
- 27.14.3 Demographic Reach and Achievements
- 27.14.4 Company News and Developments
- 27.14.5 Certifications
- 27.15 Biogen
- 27.15.1 Financial Analysis
- 27.15.2 Product Portfolio
- 27.15.3 Demographic Reach and Achievements
- 27.15.4 Company News and Developments
- 27.15.5 Certifications
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
